Takeda Pharmaceutical Company Limited provided consolidated earnings guidance for year ending March 31, 2023. For the period, the company expected revenue of JPY 3,690,000 million, operating profit of JPY 520,000 million, profit attributable to owners of parent of JPY 292,000 million, Basic earnings per share of JPY 188.13 per basic share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,130 JPY | -0.19% | +0.02% | +1.87% |
May. 16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
May. 15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.87% | 41.69B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for Year Ending March 31, 2023